6533b872fe1ef96bd12d3a59
RESEARCH PRODUCT
Three-arm randomized phase II study evaluating oral vinorelbine plus capecitabine versus paclitaxel plus gemcitabine versus docetaxel plus gemcitabine as first-line chemotherapy in patients with metastatic breast cancer: Final results (NorCap-CA223 trial)
Philippe BougnouxC. F. SlabberG. VillanovaKadri AltundagRustem KhasanovAgustí BarnadasPatricia DodykSaverio CinieriMarcus SchmidtAnn VandebroekDaniel RauchDar-ren ChenNicole Tubiana-mathieuMichiel BothaMaria Jose GodesUgur CoskunJ. CárdenasArlene ChanJavier Castellanos DiezSilvia Lazzarellisubject
OncologyCancer Researchmedicine.medical_specialtybusiness.industryStandard treatmentCombination chemotherapymedicine.diseaseVinorelbineMetastatic breast cancerGemcitabineCapecitabinechemistry.chemical_compoundOncologyDocetaxelPaclitaxelchemistryInternal medicinemedicinebacteriaskin and connective tissue diseasesbusinessmedicine.drugdescription
1044 Background: Combination chemotherapy (CT) is among the standard treatment options in metastatic breast cancer (MBC), especially in patients (pts) with visceral metastases or need of rapid symp...
year | journal | country | edition | language |
---|---|---|---|---|
2014-05-20 |